Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medisys PLC

This article was originally published in The Gray Sheet

Executive Summary

Ipswich, U.K. maker of safety syringes raises approximately $69.9 mil. through placement of 37.6 mil. New Ordinary Shares at about $1.86 per share (based on current exchange rates). A portion of the proceeds from the offering will be used to gear up manufacturing efforts for the Futura safety syringe, for which a 510(k) is pending at FDA (1"The Gray Sheet" July 12, 1999, p. 6). The funds also will be used to develop and acquire additional safety products to complement the Futura line, and to "establish a U.S. sales and marketing infrastructure" for next generation blood glucose monitoring systems slated to debut later this year. Nomura International was underwriter for the offering, and the shares trade on the Alternative Investment Market

You may also be interested in...

Medisys' Futura Plans Include Entry Into Growing U.S. Safety Needle Market

Medisys plc's acquisition of the Futura safety syringe from Adventec would provide the firm with a means to tap into the growing demand in the U.S. for sharps with protective features designed to reduce accidental needlesticks among health care workers.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts